Takeda Pharmaceutical Company Limited (TAK) has been in the limelight as a cheap pharmaceutical stock to buy according to short sellers. Its position has further been raised by Van ECK Associates Corp.
Individual investors have the majority stake in the company with 52% ownership, followed by institution's 46%. The stock, despite needing to grow net profits, seems attractive. Encouraging signals indicate a positive trend with the company unveiling an
employee incentive plan and even announcing new assignments of directors. Signs point towards Takeda achieving strong quarterly growth, and an upswing in dividends as compared to last year. Moreover, they beat Q1 2025 earnings expectations. An investment with Takeda Pharmaceutical has seen shareholders earn a 8.8% CAGR over the last three years. Despite a temporary dip, it is said to have turned around, which has led to the conclusion of share issuance and an operational profit decline. However, it recorded mixed results in Soticlestat trials. A recent partnership with AC Immune has brought funds forward to drive the pipeline. The company has also successfully announced
new FDA approvals which bodes well for future growth.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Sun, 01 Sep 2024 15:17:52 GMT -
Rating 7
- Innovation 3
- Information 10
- Rumor -6
